Hyperbaric oxygen therapy ameliorates inflammation by modulating dysbiosis of the gut microbiota in Crohn’s Disease

The hallmark of Crohn’s disease (CD) is systemic inflammation, along with intestinal inflammation that extends through all layers of the gut wall.

Hyperbaric Oxygen (HBOT) has been shown to cause a significant reduction in the inflammatory markers in CD while also showing clinical improvements in these patients. Emerging evidence suggests that gut microbiota plays a predominant role in in CD and is associated with the progression of CD. Since HBOT has been shown to regulate gut microbiota, this study was aimed to observe the effects in CD.

Their findings demonstrated that HBOT was able to mitigate the altered composition of gut microbiota and improve the reduced microbial diversity found in CD.  By regulating the gut micorbiota, HBOT was able to help ameliorate intestinal inflammation along with systemic inflammation.<view study>